Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Foghorn Therapeutics Inc's Business Segments
Foghorn Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
The
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- The100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| The | $ 3 | 100% |
Description of Foghorn Therapeutics Inc
Foghorn Therapeutics Inc. is a biotechnology company that specializes in the discovery and development of novel therapeutics based on the emerging field of chromatin biology. The company focuses on harnessing the power of gene regulation and chromatin regulation to develop treatments for various complex diseases, including cancer and neurological disorders.
At the core of Foghorn Therapeutics' research and development efforts is the understanding that genes are not just static entities but are dynamically regulated by a complex interplay between DNA, RNA, and proteins. This dynamic regulation is controlled by chromatin, which is the complex of DNA and proteins that forms the chromosomes within the nucleus of a cell.
By studying the role of chromatin regulation in disease biology, Foghorn Therapeutics aims to identify and develop novel therapies that can modulate the expression of genes to restore healthy cellular functions. This approach offers the potential to target disease-specific pathways that are not easily treatable with current therapeutic modalities.
Foghorn Therapeutics employs a multidisciplinary team of scientists and experts in the fields of genomics, bioinformatics, chemistry, and drug discovery. They utilize cutting-edge technologies and platforms, including advanced genomic sequencing, high-throughput screening, and artificial intelligence, to identify and validate potential targets for therapeutic intervention.
One of the key strengths of Foghorn Therapeutics lies in its proprietary platform called Gene Traffic Control (GTC), which enables the discovery and development of small molecules that can modulate the function of chromatin regulators. GTC integrates various genomic and functional genomic data sets to identify key regulatory nodes within the chromatin regulatory network that can be targeted therapeutically.
The company has a pipeline of potential therapeutic candidates across multiple disease areas, with a particular focus on oncology. Foghorn Therapeutics aims to develop precision medicines that can selectively target specific disease-driving genes or pathways, while minimizing off-target effects and toxicity.
Foghorn Therapeutics has also established strategic partnerships with leading academic institutions and other biopharmaceutical companies to leverage their expertise and access additional resources. These collaborations enable the company to accelerate its drug discovery and development programs and increase its chances of success.
In summary, Foghorn Therapeutics Inc. is a biotechnology company using innovative approaches in chromatin biology to develop targeted therapies for complex diseases. With its expertise in gene regulation, proprietary platform, and collaborative partnerships, Foghorn Therapeutics is poised to make significant advancements in the field of precision medicine.
At the core of Foghorn Therapeutics' research and development efforts is the understanding that genes are not just static entities but are dynamically regulated by a complex interplay between DNA, RNA, and proteins. This dynamic regulation is controlled by chromatin, which is the complex of DNA and proteins that forms the chromosomes within the nucleus of a cell.
By studying the role of chromatin regulation in disease biology, Foghorn Therapeutics aims to identify and develop novel therapies that can modulate the expression of genes to restore healthy cellular functions. This approach offers the potential to target disease-specific pathways that are not easily treatable with current therapeutic modalities.
Foghorn Therapeutics employs a multidisciplinary team of scientists and experts in the fields of genomics, bioinformatics, chemistry, and drug discovery. They utilize cutting-edge technologies and platforms, including advanced genomic sequencing, high-throughput screening, and artificial intelligence, to identify and validate potential targets for therapeutic intervention.
One of the key strengths of Foghorn Therapeutics lies in its proprietary platform called Gene Traffic Control (GTC), which enables the discovery and development of small molecules that can modulate the function of chromatin regulators. GTC integrates various genomic and functional genomic data sets to identify key regulatory nodes within the chromatin regulatory network that can be targeted therapeutically.
The company has a pipeline of potential therapeutic candidates across multiple disease areas, with a particular focus on oncology. Foghorn Therapeutics aims to develop precision medicines that can selectively target specific disease-driving genes or pathways, while minimizing off-target effects and toxicity.
Foghorn Therapeutics has also established strategic partnerships with leading academic institutions and other biopharmaceutical companies to leverage their expertise and access additional resources. These collaborations enable the company to accelerate its drug discovery and development programs and increase its chances of success.
In summary, Foghorn Therapeutics Inc. is a biotechnology company using innovative approaches in chromatin biology to develop targeted therapies for complex diseases. With its expertise in gene regulation, proprietary platform, and collaborative partnerships, Foghorn Therapeutics is poised to make significant advancements in the field of precision medicine.
Foghorn Therapeutics Inc. was an innovative biotechnology company that primarily focuses on developing and commercializing therapies for cancer and other serious diseases. The company utilizes its proprietary Gene Traffic Control platform to discover and develop new therapeutics. This platform is based on the understanding of chromatin regulatory processes, which play a crucial role in gene expression and are implicated in various diseases.
Segments
1. Oncology:
Foghorn Therapeutics is primarily concentrated on the oncology segment, where it aims to target genetically defined cancers. The company identifies specific vulnerabilities in cancer cells that arise from chromatin dysregulation. Their approach is designed to precisely modulate gene expression in tumor cells, thus potentially reversing their malignant behavior and presenting new therapeutic opportunities.
2. Epigenetic Therapies:
The companys work fundamentally revolves around epigenetics, allowing for novel interventions that may alter genetic expression without changing the underlying DNA sequence. This segment serves as a basis for creating a wide array of therapeutics, targeting various diseases beyond just cancers.
Products and Services
Product Candidates:
1. FGN-1:
Foghorns lead candidate, FGN-1, is an investigational therapeutic aimed at treating specific types of cancers characterized by mutations or dysregulation in key chromatin modifiers. Research around FGN-1 focuses on its ability to inhibit cancer cell proliferation and induce apoptosis selectively in malignant cells.
2. Additional Therapeutics:
The company has a pipeline of additional therapeutics in various stages of preclinical and clinical development. These candidates are also designed to address specific mutations or alterations within cancer cell mechanisms, with ongoing explorations into how they can be optimized for better efficacy and safety profiles.
Services:
1. Research collaborations:
Foghorn may engage in partnerships with academic institutions, biopharmaceutical companies, and research organizations to further study the mechanisms behind chromatin regulation and its implications for therapeutic development. This collaborative effort aids in expanding their research capabilities and validating their approaches.
2. Platform Technology Licensing:
They leverage their Gene Traffic Control platform to potentially offer licensing opportunities to other biotech and pharmaceutical companies, which can benefit from their research and development capabilities concerning chromatin regulation.
3. Data and Insights:
Foghorn Therapeutics may provide insights into gene expression patterns and chromatin regulation mechanisms to collaborators and partners. This expertise can be integral to developing therapeutic strategies based on genetic and epigenetic understanding.
Summary
To summarize, Foghorn Therapeutics Inc. focuses extensively on the design and development of therapeutics primarily in the oncology sector, utilizing its unique understanding of chromatin dynamics to inform its drug discovery. With an array of investigational candidates like FGN-1 and an emphasis on research partnerships and platform technology, the company seeks to innovate in the realm of epigenetic therapies. Their ongoing work in the pipeline illustrates a commitment to addressing genetic and epigenetic causes of cancer, providing avenues for potentially transformative treatment options.
,
Segments
1. Oncology:
Foghorn Therapeutics is primarily concentrated on the oncology segment, where it aims to target genetically defined cancers. The company identifies specific vulnerabilities in cancer cells that arise from chromatin dysregulation. Their approach is designed to precisely modulate gene expression in tumor cells, thus potentially reversing their malignant behavior and presenting new therapeutic opportunities.
2. Epigenetic Therapies:
The companys work fundamentally revolves around epigenetics, allowing for novel interventions that may alter genetic expression without changing the underlying DNA sequence. This segment serves as a basis for creating a wide array of therapeutics, targeting various diseases beyond just cancers.
Products and Services
Product Candidates:
1. FGN-1:
Foghorns lead candidate, FGN-1, is an investigational therapeutic aimed at treating specific types of cancers characterized by mutations or dysregulation in key chromatin modifiers. Research around FGN-1 focuses on its ability to inhibit cancer cell proliferation and induce apoptosis selectively in malignant cells.
2. Additional Therapeutics:
The company has a pipeline of additional therapeutics in various stages of preclinical and clinical development. These candidates are also designed to address specific mutations or alterations within cancer cell mechanisms, with ongoing explorations into how they can be optimized for better efficacy and safety profiles.
Services:
1. Research collaborations:
Foghorn may engage in partnerships with academic institutions, biopharmaceutical companies, and research organizations to further study the mechanisms behind chromatin regulation and its implications for therapeutic development. This collaborative effort aids in expanding their research capabilities and validating their approaches.
2. Platform Technology Licensing:
They leverage their Gene Traffic Control platform to potentially offer licensing opportunities to other biotech and pharmaceutical companies, which can benefit from their research and development capabilities concerning chromatin regulation.
3. Data and Insights:
Foghorn Therapeutics may provide insights into gene expression patterns and chromatin regulation mechanisms to collaborators and partners. This expertise can be integral to developing therapeutic strategies based on genetic and epigenetic understanding.
Summary
To summarize, Foghorn Therapeutics Inc. focuses extensively on the design and development of therapeutics primarily in the oncology sector, utilizing its unique understanding of chromatin dynamics to inform its drug discovery. With an array of investigational candidates like FGN-1 and an emphasis on research partnerships and platform technology, the company seeks to innovate in the realm of epigenetic therapies. Their ongoing work in the pipeline illustrates a commitment to addressing genetic and epigenetic causes of cancer, providing avenues for potentially transformative treatment options.
,